Gulnara Abdilova

Gulnara Abdilova

Auto-generated profile, based on publicly available information

Gulnara Abdilova

«Scientific Center of Pediatrics and Pediatric Surgery» JSC

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZDZaure Dushimova
Zaure Dushimova
TSTimur Saliev
Timur Saliev
ABAigul Bazarbayeva
Aigul Bazarbayeva
GNGaukhar Nurzhanova
Gaukhar Nurzhanova
ABAinura Baibadilova
Ainura Baibadilova
IFIldar Fakhradiyev
Ildar Fakhradiyev
Over the past decades, remarkable progress in multimodal therapy has significantly improved survival outcomes for children with cancer. Yet, considerable variability in treatment response and toxicity persists, often driven by underlying genetic differences that affect the pharmacokinetics and pharmacodynamics of anticancer drugs. Pharmacogenomics, the study of genetic determinants of drug response, offers a powerful approach to personalize pediatric cancer therapy by optimizing efficacy while minimizing adverse effects. This review synthesizes current evidence on key pharmacogenetic variants influencing the response to major classes of antineoplastic agents used in children, including thiopurines, methotrexate, anthracyclines, alkylating agents, vinca alkaloids, and platinum compounds. Established gene–drug associations such as TPMT, NUDT15, DPYD, SLC28A3, and RARG are discussed alongside emerging biomarkers identified through genome-wide and multi-omics studies. The review also examines the major challenges that impede clinical implementation, including infrastructural limitations, cost constraints, population-specific variability, and ethical considerations. Furthermore, it highlights how integrative multi-omics, systems pharmacology, and artificial intelligence may accelerate the translation of pharmacogenomic data into clinical decision-making. The integration of pharmacogenomic testing into pediatric oncology protocols has the potential to transform cancer care by improving drug safety, enhancing treatment precision, and paving the way toward ethically grounded, personalized therapy for children.

30 December 2024 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
EKEdil Kurakbayev
Edil Kurakbayev
KUKuanysh Umbetov
Kuanysh Umbetov
YSYergali Sarsekbayev
Yergali Sarsekbayev
BTBotagoz Turdaliyeva
Botagoz Turdaliyeva
LMLyazat Manzhuova
Lyazat Manzhuova
GAGulnara Abdilova
Gulnara Abdilova
Aim: The aim is to highlight the importance of early detection, the efficacy of pediatric early warning signs (PEWS), and their implications for clinical practice, focusing on the specific signs that affect the detection and management of clinical deterioration in children with oncological diseases.Methods: The review included English-language studies retrieved from common databases using the keywords “pediatric,” “Early Warning Signs,” “clinical deterioration,” combined with terms related to “onchohematological” and “pediatric cancers.”Results: Sixteen articles were analyzed. The analysis revealed that the PEWS cohort was associated with a lower incidence of unplanned codes (p = 0.0001), cardiopulmonary arrest (P = 0.0001), and mortality (P = 0.01). The incidence of critical deterioration between the cohorts showed no significant variation (P = 0.07).Conclusion: PEWS significantly contributes to reducing mortality rates, unplanned codes, and cardiopulmonary arrest. However, further research is required to address the limitations and challenges associated with its application in this population

29 June 2023 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
EKEdil Kurakbayev
Edil Kurakbayev
BTB. Turdaliyeva
B. Turdaliyeva
LMLyazat Manzhuova
Lyazat Manzhuova
KOK. Omarova
K. Omarova
GAG. Abdilova
G. Abdilova
VSV. Schukin
V. Schukin
Relevance: Oncological diseases remain the main cause of death in children, increasing the need for intensive care. Hospitalized children suffering from oncological diseases are at high risk for sudden deterioration of their condition, both for the underlying disease and due to infectious complications and the toxic effects of medications. This review highlights information on the Pediatric Early Warning Signs (PEWS) system in oncological patients to detect clinical deterioration promptly. The study aimed to analyze international literature on the use of pediatric early warning signs (PEWS) for clinical deterioration in pediatric oncology. Methods: Current literature on using the PEWS of clinical deterioration in pediatric oncology was studied. Results: The published data show the important role of using the PEWS system in cancer patients for early detection of deterioration of the condition with subsequent provision of emergency medical care. Conclusion: The analysis of international experience has shown that using the PEWS system in children with oncological diseases is an effective method of early recognition of signs of clinical deterioration, which, in turn, allows the timely initiation of complex intensive therapy.

30 June 2023 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
EKEdil Kurakbayev
Edil Kurakbayev
BTB. Turdaliyeva
B. Turdaliyeva
LMLyazat Manzhuova
Lyazat Manzhuova
KOK. Omarova
K. Omarova
GAG. Abdilova
G. Abdilova
VSV. Schukin
V. Schukin
Relevance: Oncological diseases remain the main cause of death in children, increasing the need for intensive care. Hospitalized children suffering from oncological diseases are at high risk for sudden deterioration of their condition, both for the underlying disease and due to infectious complications and the toxic effects of medications. This review highlights information on the Pediatric Early Warning Signs (PEWS) system in oncological patients to detect clinical deterioration promptly. The study aimed to analyze international literature on the use of pediatric early warning signs (PEWS) for clinical deterioration in pediatric oncology. Methods: Current literature on using the PEWS of clinical deterioration in pediatric oncology was studied. Results: The published data show the important role of using the PEWS system in cancer patients for early detection of deterioration of the condition with subsequent provision of emergency medical care. Conclusion: The analysis of international experience has shown that using the PEWS system in children with oncological diseases is an effective method of early recognition of signs of clinical deterioration, which, in turn, allows the timely initiation of complex intensive therapy.

28 April 2026 in Ocular Oncology and Pathology
Verified
Journal Article
Closed access
AAAlua Aubakirova
Alua Aubakirova
AAAkmaral Abikulova
Akmaral Abikulova
LMLyazat Manzhuova
Lyazat Manzhuova
NANazgul Akhtayeva
Nazgul Akhtayeva
AIAigulsum Izekenova
Aigulsum Izekenova
NANeilya Aldasheva
Neilya Aldasheva
Introduction: Retinoblastoma (Rb) is a rare but aggressive pediatric eye cancer. This study aimed to examine its epidemiological characteristics, diagnostic stages, and survival factors in Kazakhstan, where national-level data have previously been limited. Methods: A retrospective national registry study was conducted using data from the Scientific Center for Pediatrics and Pediatric Surgery, the country’s referral center for Rb (2015–2024). Incidence was calculated using a birth cohort approach per 100,000 live births. Demographic and clinical characteristics, including diagnostic intervals (lag time 1: symptom onset to diagnosis; lag time 2: diagnosis to treatment initiation), were analyzed. Survival was estimated using Kaplan-Meier methods. Prognostic factors were assessed using univariate and multivariable Cox proportional hazards regression. Results: A total of 167 cases were recorded. The cumulative birth cohort incidence was 4.18 per 100,000 live births (1:23,915). Median age at diagnosis was 14 months (IQR: 6.5–27.5). Unilateral disease occurred in 78.4% of patients, and 76.9% were diagnosed at advanced stages (D or E). Extraocular involvement was observed in 9.8% of affected eyes. Hereditary Rb accounted for 6% of cases. Median lag time 1 was 60 days (IQR: 30–120), and median lag time 2 was 12 days (IQR: 7–20). Overall mortality was 11.4%, with most deaths occurring within 18 months. Older age at diagnosis (adjusted HR: 1.031; 95% CI: 1.008–1.054; p = 0.009) and longer lag time 2 (adjusted HR: 1.006; 95% CI: 1.004–1.008; p < 0.001) were independently associated with increased mortality. Conclusion: Rb in Kazakhstan remains characterized by a high proportion of advanced-stage disease and measurable early mortality. Delays in treatment initiation and older age at diagnosis independently predict poorer survival, underscoring the need to strengthen early detection and optimize care pathways.

30 August 2026 in Наука и здравоохранение
Verified
Journal Article
Closed access
GTG.T. Tashenova
G.T. Tashenova
GAG.K. Abdilova
G.K. Abdilova
DKD.N. Kairbaeva
D.N. Kairbaeva
ASA. Sarmoldina
A. Sarmoldina
RSR.F. Sabitova
R.F. Sabitova
MRM.R. Rabandiyarov
M.R. Rabandiyarov
Introduction.Minimal residual disease (MRD) is a key predictor of relapse and survival in pediatric acute lymphoblastic leukemia (ALL), as well as a central component of risk-adapted treatment protocols, including the BFM approach. [1,2] Aim. To present data from a systematic review on MRD monitoring in pediatric ALL and to compare the advantages and prognostic value of the main MRD detection methods (multicolor/next-generation flow cytometry, Ig/TCR-RQ-PCR, and NGS), as well as factors influencing the reliability of results. Search strategy. A systematic search was conducted in PubMed and Scopus databases and peer-reviewed journals covering publications from 2010 to 2025. Studies on pediatric ALL describing MRD detection methods, time points of assessment, and treatment outcomes (EFS/OS/relapse), as well as current guidelines defining MRD standards, were included. Results. MRD levels reflect the effectiveness of treatment protocols and clinical management strategies, including treatment intensification in patients with disease progression and consideration of alternative therapeutic approaches in cases of persistent MRD. [15,16] Within the BFM protocol, the most significant MRD is observe d on day 15 and at the end of induction therapy (day 33), with a broad threshold of 10⁻⁴(0.01%). [3,4] Multicolor flow cytometry (MFC/NGF) enables rapid decision-making, while molecular methods (Ig/TCR-RQ-PCR, NGS) improve analytical sensitivity and reproducibility, maintaining standard quality parameters (LOD/LOQ, QA, hemodilution control). [1,5,6] MRD dynamics between days 15 and 33 provide independent prognostic information. [3,7] Conclusions. MRD monitoring in pediatric acute lymphoblastic leukemia is an essential component of risk-adapted therapy. For clinical application, standardized bone marrow sampling, defined limits of detection and quantification, and consistent interpretation of MRD levels and their dynamics according to protocol are required. [1,5,6] Введение. Минимальная остаточная болезнь (МОБ) - это основной предиктор рецидива и выживаемости при остром лимфобластном лейкозе (ОЛЛ) у детей, а также ключевой элемент риск-адаптированных протоколов, включая подход BFM. [1,2] Цель. Представить данные систематического обзора о мониторинге МОБ при ОЛЛ у детей и сравнить преимущества и прогностическую ценность основных методов обнаружения МОБ (многоцветная/проточная цитометрия следующего поколения, Ig/TCR-RQ-PCR, NGS) и факторы, определяющие надежность результатов. Стратегия поиска. Был проведен систематический поиск в базах данных PubMed, Scopus, журналов по публикациям за с 2010 по 2025 год. Включены исследования по детскому ОЛЛ, описывающие методы определения МОБ, временные точки и результаты лечения (EFS/OS/рецидив), а также текущие руководства приводящие к стандарту МОБ. Результаты. Показатели МОБ отражают эффективность протоколов и тактики ведения: интенсификация лечения у пациентов с прогрессированием и обсуждение альтернативных методов лечения при персистирующей МОБ [15,16]. В BFM-подходе наиболее значительная МОБ наблюдается на 15-й день и в конце индукции (33-й день) с пороговым значением широкого спектра 10⁻⁴ (0,01%). [3,4] Многоцветная проточная цитометрия (MCF/NGF) обеспечивает высокую нагрузку и скорость принятия решения; молекулярные методы (Ig/TCR-RQ-PCR, NGS) повышают аналитическую чувствительность и воспроизводимость при сохранении стандартных показателей качества (LOD/LOQ, QA, контроль гемодилюции). [1,5,6] Динамика разрешения МОБ в период с 15 по 33 день предоставляет независимую прогностическую информацию. [3.7] Выводы: Мониторинг МОБ у детей с острым лимфобластным лейкозом является важным компонентом терапии, адаптированной к риску. Для клинического применения необходимы стандартизированный забор костного мозга, определение пределов обнаружения и количественного определения, интерпретация уровней МОБ и их динамики в соответствии с протоколом. [1,5,6] Кіріспе. Минималды қалдық ауру (МОА) — балалардағы жедел лимфобластты лейкоз (ЖЛЛ) кезінде рецидив пен өмір сүру ұзақтығының негізгі болжамдық көрсеткіші, сондай-ақ BFM тәсілін қоса алғанда, қауіпке бейімделген хаттамалардың маңызды элементі болып табылады. [1,2] Мақсаты. Балалардағы ЖЛЛ...